BioNeutral Secures Three Initial Trial Orders for its Ogiene(TM) Odor Neutralizer & Multi-Purpose Cleaner Product Line

NEWARK, N.J. and LOUISVILLE, Ky., March 8, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced that it has received three new initial trial orders for its highly diverse Ogiene line of unregulated products.

The initial orders were made by Indiana-based Oakland City University, Kentucky-based Grayson County Fiscal Court House, and Exceptional Teens and Adults (ETA), which is a structured program providing care and support to teens and adults that have been diagnosed with intellectual or developmental disabilities.

The orders, which resulted from the BioNeutral executive team’s recent trip to Kentucky, are the first in what is expected to be a long-term relationship with BioNeutral and its game changing line of products, for each organization involved.

The Ogiene odor eliminating product line has received acclaim in life sciences circles for its ability to neutralize odors with a dramatic increase in speed and power over its rivals in the marketplace. Its multi-purpose cleaner and stain remover has repeatedly proven its effectiveness and ease of use in direct consumer based field trials. Ogiene’s proprietary technology platform has been proven highly effective in both surface and airborne applications. Other formulas that will soon be introduced into the market are the Sport Odor Eliminator (for use on all sports equipment), Graffiti Remover and White Board Rejuvenator. All of the Ogiene products are environmentally safe and do not harm the worlds food supply.

This announcement continues to build on the momentum which BioNeutral has achieved since the beginning of the year. Last week, the company announced that the EPA has granted its approval and registration (Reg No: 81242-1) for BioNeutral’sYgiene antimicrobial product line, after an intensive six month review & several years of R&D.

“We are pleased to see our efforts in Kentucky begin to show positive movement with these initial orders made by Oakland City University, Grayson County Fiscal Court House and Exceptional Teens and Adults, for our unregulated Ogiene line of products,” said Stephen J. Browand President and CEO of BioNeutral Group, Inc. “Once people use these various Ogiene products in a real world application they quickly become believers, that our product claims are true.”

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral’s products, Ygiene and Ogiene, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking Statements

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company’s filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company’s technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company’s data and findings specific to Ygiene -206. BioNeutral’s antimicrobial formulations will be marketed under the brand name Ygiene and will soon be available for sale in the United States.

SOURCE BioNeutral Group, Inc.